A Phase I Clinical Trial of mTOR Inhibition With Sirolimus for Enhancing ALVAC(2)-NY-ESO-1(M)/TRICOM Vaccine Induced Anti-Tumor Immunity in Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cancer vaccine vCP2292 (Primary) ; Sirolimus (Primary) ; Sargramostim
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 27 Mar 2020 Biomarkers information updated
- 13 Nov 2012 Planned number of patients changed from 42 to 36 as reported by ClinicalTrials.gov record.
- 20 Aug 2012 Actual initiation date (1 Aug 2012) added as reported by ClinicalTrials.gov record.